Front > Comment


Amiram Barkat  illustration: Gil Gibli Israel's budget surpluses are becoming a habit

Will 2017's NIS 10 billion budget surplus - the fifth consecutive such annual surplus - be used for cutting government debt or buying voters with tax cuts? 

Eli Tsipori  illustration: Gil Gibli Teva a victim of Copaxone's success

Teva's reliance on Copaxone made the company complacent, obese, and excessively self-confident.

Amiram Barkat  illustration: Gil Gibli Is doing business in Israel getting easier? Depends whom you ask

Israel has moved up the World Economic Forum rankings, but has deteriorated according to the World Bank Doing Business index.

Norman Bailey  illustration: Gil Gibli Media overlooks Sunni Arabs' Israel overtures

Bahrain, Saudi Arabia and Egypt are among the region's countries warming to Israel.

Eli Tsipori  illustration: Gil Gibli Sano toiletries outstrip rivals in profitability

The government is criticizing the high prices charged by toiletries importers while the industry profit margins leader is local manufacturer Sano.

Dror Marmor  illustration: Gil Gibli As housing demand slows, so does supply

Building starts in 2017 will be far less than Israel needs, despite the government's promises.

Shiri Habib-Valdhorn  illustration: Gil Gibli Teva: Right person, wrong time?

Kåre Schultz has turned a company round before, but the challenge at Teva is huge.

Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017